Semaglutide and tirzepatide are not metabolized through cytochrome P450 enzymes, so they dont affect SSRI metabolism
Patients are strongly advised to consult their GP before using any weight-management compound, and to disclose all substances currently being taken to ensure safe and coordinated care
Your doctor should assess several factors before approving discontinuation, including your current weight status and trajectory, the presence and control of obesity-related comorbidities (type 2 diabetes, hypertension, sleep apnea, cardiovascular disease), your readiness and capacity to implement intensive lifestyle modifications, available support systems and resources, and your history of weight cycling or previous weight loss attempts
The effect of Tirzepatide on body composition in people with overweight and obesity: a systematic review of randomized, controlled studies
Variants in the GIPR gene have been independently associated with BMI, fat distribution, and response to dual incretin agonism